Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 9/20 | 0.37 |
| ▸ | HEXB | P07686 | 2/20 | 0.37 |
| ▸ | PYGB | P11216 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HEXA | P06865 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816363 | 1.00 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL14753651 | 1.00 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL18390982 | 1.00 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL25011181 | 1.00 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL17816418 | 1.00 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL12899657 | 0.93 | OGA (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL12150224 | 0.93 | OGA (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL15962116 | 0.93 | OGA (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL21738820 | 0.93 | OGA (0.41) | LGALS1LGALS3LGALS9LGALS8OGA | |
| SCHEMBL7603749 | 0.93 | OGA (0.41) | LGALS1LGALS3LGALS9LGALS8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210108247-A1 | CHEMOENZYMATIC SYNTHESIS OF TREHALOSE ANALOGUES | CENTRAL MICHIGAN UNIVERSITY | 2021-04-15 | — | — | US | disclosed |
| EP-3356385-B1 | 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | DEUTSCHES KREBSFORSCH (DE) | 2020-11-11 | — | — | EP | disclosed |
| WO-2017136739-A1 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210108247-A1 | CHEMOENZYMATIC SYNTHESIS OF TREHALOSE ANALOGUES | TREH, TALDO1, TKT | LGALS1 1051/4885LGALS3 1100/4885LGALS9 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.